DNLI Denali Therapeutics Inc.

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials and DNL151, which are in Phase 1 and Phase 1b clinical trials for Parkinson's disease. It is also developing receptor interacting serine/threonine protein kinase 1 (RIPK1) product candidates, such as DNL747, a selective and brain-penetrant small molecule RIPK1 inhibitor product candidate that is in Phase 1b clinical trial for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). In addition, the company develops enzyme transport vehicle: iduronate 2-sulfatase, an enzyme replacement therapy program for MPS II, a lysosomal storage disorder; antibody transport vehicle (ATV): alpha-synuclein (aSyn) program, a protein that spreads throughout the brain in Parkinson's disease; ATV: triggering receptor expressed in myeloid cells 2, a therapeutic candidate designed to rescue microglial function in Alzheimer's disease; and ATV: Tau, a therapeutic targeting the spreading of Tau. Denali Therapeutics Inc. has collaboration agreement with Takeda Pharmaceutical Company and Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, Centogene, and MedGenome Labs Private Ltd; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Recent Analyst Ratings for Denali Therapeutics Inc.

Date	Price Target	Rating	Analyst
4/10/2025		Neutral → Overweight	Cantor Fitzgerald
3/7/2025	$41.00 → $33.00	Overweight	Morgan Stanley
2/11/2025	$31.00	Buy	Deutsche Bank
1/7/2025	$31.00	Outperform	Robert W. Baird
1/3/2025		Outperform	William Blair
12/16/2024	$37.00	Hold → Buy	Stifel
10/10/2024		Mkt Perform	Raymond James
10/7/2024		Overweight → Neutral	Cantor Fitzgerald
12/13/2023	$32.00	Buy	Citigroup
11/20/2023	$28.00	Overweight	JP Morgan

See more ratings

Denali Therapeutics Inc.

Peers

Recent Analyst Ratings for Denali Therapeutics Inc.

Denali Therapeutics Inc. SEC Filings

Denali Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

SEC Form 10-Q filed by Denali Therapeutics Inc.

Denali Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form DEFA14A filed by Denali Therapeutics Inc.

SEC Form DEF 14A filed by Denali Therapeutics Inc.

Denali Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

Denali Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure

SEC Form S-8 filed by Denali Therapeutics Inc.

Denali Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Results of Operations and Financial Condition, Financial Statements and Exhibits

SEC Form S-3ASR filed by Denali Therapeutics Inc.

Denali Therapeutics Inc. Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

Director Baker Bros. Advisors Lp was granted 21,130 shares (SEC Form 4)

New insider Baker Bros. Advisors Lp claimed ownership of 3,731,695 shares (SEC Form 3)

SEC Form 3 filed by new insider Baker Julian

Director Cook Jennifer E. was granted 6,037 shares, increasing direct ownership by 30% to 26,075 units (SEC Form 4)

Director Flatley Jay T was granted 6,037 shares, increasing direct ownership by 59% to 16,220 units (SEC Form 4)

Director Klein Peter S was granted 6,037 shares, increasing direct ownership by 28% to 27,533 units (SEC Form 4)

Director Krognes Steve E. was granted 6,037 shares, increasing direct ownership by 23% to 31,794 units (SEC Form 4)

Director Schenkein David P was granted 6,037 shares, increasing direct ownership by 65% to 15,257 units (SEC Form 4)

Director Thornberry Nancy was granted 6,037 shares, increasing direct ownership by 32% to 24,717 units (SEC Form 4)

Director Tessier-Lavigne Marc was granted 6,037 shares, increasing direct ownership by 0.32% to 1,886,576 units (SEC Form 4)

Denali Therapeutics Inc. Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

Denali Therapeutics upgraded by Cantor Fitzgerald

Morgan Stanley resumed coverage on Denali Therapeutics with a new price target

Deutsche Bank initiated coverage on Denali Therapeutics with a new price target

Robert W. Baird initiated coverage on Denali Therapeutics with a new price target

William Blair initiated coverage on Denali Therapeutics

Denali Therapeutics upgraded by Stifel with a new price target

Raymond James resumed coverage on Denali Therapeutics

Denali Therapeutics downgraded by Cantor Fitzgerald

Citigroup initiated coverage on Denali Therapeutics with a new price target

JP Morgan resumed coverage on Denali Therapeutics with a new price target